Novel dual Src/Abl inhibitors for hematologic and solid malignancies.

Schenone, Silvia

Novel dual Src/Abl inhibitors for hematologic and solid malignancies. [electronic resource] - Expert opinion on investigational drugs Aug 2010 - 931-45 p. digital

Publication Type: Journal Article; Review

1744-7658

10.1517/13543784.2010.499898 doi


Aniline Compounds--metabolism
Animals
Antineoplastic Agents--pharmacology
Benzodioxoles--metabolism
CSK Tyrosine-Protein Kinase
Clinical Trials as Topic
Dasatinib
Dogs
Drug Evaluation, Preclinical
Fusion Proteins, bcr-abl--antagonists & inhibitors
Hematologic Neoplasms--drug therapy
Humans
Mice
Mice, Knockout
Mice, Nude
Mice, SCID
Neoplasms--drug therapy
Nitriles--metabolism
Protein Kinase Inhibitors--metabolism
Protein-Tyrosine Kinases--antagonists & inhibitors
Pyrimidines--metabolism
Quinazolines--metabolism
Quinolines--metabolism
Rats
Thiazoles--metabolism
Triazines--metabolism
src-Family Kinases